Ascendis Pharma - All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis - Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows termination of the collaboration agreement between Ascendis and Novo Nordisk A/S announced in November 2024.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.